Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis

Clinical and Experimental Allergy

Volumn 38, Issue 2, 2008, Pages 329-337

  Nagakura, T ^a   Ogino, S ^b   Okubo, K ^c   Sato, N ^d   Takahashi, M ^d   Ishikawa, T ^e  

^a Yoga Allergy Clinic   (Japan)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

^d NOVARTIS PHARMA K K   (Japan)

^e KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Anti IgE antibody; Omalizumab; Seasonal allergic rhinitis; Suplatast tosilate

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN E; OMALIZUMAB; PLACEBO; SUPLATAST TOSYLATE;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EYE; FEMALE; GASTROINTESTINAL DISEASE; HAY FEVER; HEADACHE; HISTORY; HUMAN; INJECTION SITE BLEEDING; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; JAPANESE CEDAR; MAJOR CLINICAL STUDY; MALAISE; MALE; NOSE; POLLEN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SCORING SYSTEM; SKIN DISEASE; SNEEZING; SOMNOLENCE; STATISTICAL SIGNIFICANCE; SYMPTOM; TH2 CELL; URETER STONE;

ADULT; ANTI-ALLERGIC AGENTS; ANTIBODIES, MONOCLONAL; ARYLSULFONATES; ASIAN CONTINENTAL ANCESTRY GROUP; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN E; JAPAN; MALE; MIDDLE AGED; POLLEN; RHINITIS, ALLERGIC, SEASONAL; SULFONIUM COMPOUNDS; TREATMENT OUTCOME;

EID: 38349133719     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2007.02894.x     Document Type: Article

References (39)

1. Okuda M. Epidemiology of Japanese cedar pollinosis throughout Japan. Ann Allergy Asthma Immunol 2003 91: 288 96.
2. Okubo K, Gotoh M, Shimada K et al. Fexofenadine improves the quality of life and work productivity in Japanese patients with seasonal allergic rhinitis during the peak cedar pollinosis season. Int Arch Allergy Immunol 2005 136: 148 54.
3. Presta LG, Lahr SJ, Shields RL et al. Humanization of an antibody directed against IgE. J Immunol 1993 151: 2623 32.
4. Shields RL, Whether WR, Zioncheck K et al. Inhibition of allergic reactions with antibody to IgE. Int Arch Allergy Immunol 1995 107: 308 12.
5. Beck LA, Marcotte GV, MacGlashan D Jr. et al. Omalizumab-induced reductions in mast cell FcεRI expression and function. J Allergy Clin Immunol 2004 114: 527 30.
6. Coyle AJ, Wagner K, Bertrand C et al. Central role of immunoglobulin (Ig) E in the reduction of lung eosinophil infiltration and T helper 2 cell cytokine production: inhibition by a non-anaphylactogenic anti-IgE antibody. J Exp Med 1996 183: 1303 10.
7. Noga O, Hanf G, Kunkel G. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol 2003 131: 46 52.
8. Kopp MV, Brauburger J, Riedinger F et al. The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis. J Allergy Clin Immunol 2002 110: 728 35.
9. Hanf G, Brachmann I, Kleine-Tebbe J et al. Omalizumab decreased IgE-release and induced changes in cellular immunity in patients with allergic asthma. Allergy 2006 61: 1141 4.
10. Plewako H, Arvidsson M, Petruson K et al. The effect of omalizumab on nasal allergic inflammation. J Allergy Clin Immunol 2002 110: 68 71.
11. Djukanovic R, Wilson SJ, Kraft M et al. Effect of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004 170: 583 93.
12. Noga O, Hanf G, Brachmann I et al. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol 2006 117: 1493 9.
13. Okubo K, Ogino S, Nagakura T, Ishikawa T. Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. Allergol Int 2006 55: 379 86.
14. Tamaoki J, Kondo M, Sakai N et al. Effect of suplatast tosilate, a Th2 cytokine inhibitor, on steroid-dependent asthma: a double-blind randomised study. Lancet 2000 356: 273 8.
15. Furukido K, Takeno S, Ueda T et al. Suppression of the Th2 pathway by suplatast tosilate in patients with perennial nasal allergies. Am J Rhinol 2002 16: 329 36.
16. Kimata H. Selective enhancement of production of IgE, IgG4, and Th2-cell cytokine during the rebound phenomenon in atopic dermatitis and prevention by suplatast tosilate. Ann Allergy Asthma Immunol 1999 82: 293 5.
17. Establishment Committee of the Clinical Guideline for Allergic Rhinitis. Clinical guideline for allergic rhinitis in Japan. Perennial and seasonal allergic rhinitis, 4th Edn. Tokyo: Life Science Medica, 2002, (in Japanese).
18. Oda N, Minoguchi K, Yokoe T et al. Effect of suplatast tosilate (IPD-1151T) on cytokine production by allergen-specific human Th1 and Th2 cell lines. Life Sci 1999 65: 763 70.
19. Koda A, Yanagihara Y, Matsuura N. Ipd-1151t: a prototype drug for IgE antibody synthesis modulation. Agents Actions 1991 34 (Suppl.): 369 78.
20. Yanagihara Y, Kiniwa M, Ikizawa K, Shida T, Matsuura N, Koda A. Suppression of IgE production by IPD-1151T (suplatast tosilate), a new dimethylsulfonium agent: (2). Regulation of human IgE response. Jpn J Pharmacol 1993 61: 31 9.
21. Sano Y, Suzuki N, Yamada H et al. Effect of suplatast tosilate on allergic eosinophilic airway inflammation in patients with mild asthma. J Allergy Clin Immunol 2003 111: 958 66.
22. Sano Y, Miyamoto T, Makino S. Anti-inflammatory effect of suplatast tosilate on mild asthma. Chest 1997 112: 862 3.
23. Simons FE, Simons KJ. The pharmacology and use of H1-receptor-antagonist drugs. N Engl J Med 1994 330: 1663 70.
24. Kita H, Jorgensen RK, Reed CE et al. Mechanism of topical glucocorticoid treatment of hay fever: IL-5 and eosinophil activation during natural allergen exposure are supressed, but IL-4, IL-6, and IgE antibody production are unaffected. J Allergy Clin Immunol 2000 106: 521 9.
25. Handelman NI, Friday GA, Schwartz HJ et al. Cromolyn sodium nasal solution in the prophylactic treatment of pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 1977 59: 237 42.
26. Lipworth BJ. Emerging role of antileukotriene therapy in allergic rhinitis. Clin Exp Allergy 2001 31: 1813 21.
27. Hamilton RG, Marcotte GV, Saini SS. Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy. J Immunol Methods 2005 303: 81 91.
28. Casale TB, Bernstein L, Busse WW et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1997 100: 110 21.
29. Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. The anti-inflamatory effect of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005 115: 459 65.
30. Prussin C, Griffith DT, Boesel KM, Lin H, Foster B, Casale TB. Omalizumab treatment downregulates dendritic cell FcRεI expression. J Allergy Clin Immunol 2003 112: 1147 54.
31. Tanaka A, Minoguchi K, Samson KTR et al. Inhibitory effects of suplatast tosilate on the differentiation and function of monocyte-derived dendritic cells from patients with asthma. Clin Exp Allergy 2007 37: 1083 9.
32. Oda N, Minoguchi K, Tanaka A et al. Suplatast tosilate inhibits thymus - and activation-regulated chemokine production by antigen-specific human Th2 cells. Clin Exp Allergy 2002 32: 1782 6.
33. Konno S, Adachi M, Asano K et al. Suppressive effects of IPD-1151T (suplatast-tosilate) on induction of mast cells from normal mouse splenocytes. Eur J Pharmacol 1994 259: 15 20.
34. Ädelroth E, Rak S, Haahtela T et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000 106: 253 9.
35. Chervinsky P, Casale T, Townley R et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2003 91: 160 7.
36. Casale TB, Busse WW, Kline JN et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006 117: 134 40.
37. Kuehr J, Brauburger J, Zielen S et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002 109: 274 80.
38. Bousquet J, Van Cauwenberge P, Khaltaey N. Allergic rhinitis and its impact on asthma (ARIA) workshop report. J Allergy Clin Immunol 2001 108 (Suppl.): S147 334.
39. Vignola AM, Humbert M, Bousquet J et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patient with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004 59: 709 17.